MODERNA INC

Moderna secures $54.3 million from CEPI to fast‑track its bird‑flu vaccine, advancing Phase III trials and boosting pandemic‑preparedness prospects.

Moderna’s $1.5B credit line and first revenue rise in three years signal a strategic turnaround from its pandemic‑era focus to a diversified, mRNA‑driven growth trajectory.

Moderna Inc.’s stock price has declined significantly from its 52-week high, with a current price of $27.92, and a hypothetical $10,000 investment made in 2020 would have lost 61.75% in value by 2025.

Moderna’s stock plummeted 6.56% to a 6-month low after a report suggested the Trump administration was linking the company’s COVID-19 vaccine to the deaths of 25 children, sparking a wave of negative sentiment in the vaccine-maker sector.

Moderna Inc.’s stock has surged 6.19% to $28.74, marking a significant rebound in the biotech sector, driven by investor confidence in the company’s mRNA technology and future prospects.

Moderna’s stock surged 6.06% after the company voluntarily withdrew its BLA for a combination COVID-19 and flu vaccine, despite the broader market experiencing a decline.

Moderna Inc. saw a significant surge in its stock price on May 20, 2025, bucking the trend of a mixed market performance, amidst heightened investor interest in its mRNA technology and vaccine development efforts.

Moderna Inc.’s stock price surged amidst market fluctuations, driven by the company’s continued innovation in mRNA therapeutics and vaccines, positioning it as a leader in the biotechnology sector.

Moderna Inc. continues to navigate a dynamic biotech landscape through strategic partnerships and market fluctuations, with its focus on innovation and mRNA medicine development positioning it for long-term growth prospects.

Moderna Inc. has expanded its collaboration with Benchling, a R&D platform, to integrate AI into its research and development efforts, potentially accelerating the development of mRNA medicines for various diseases.